CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Anda juga dapat menghubungi kami: hubungi +44 2030978888 support@capital.com

Perdagangan Spero Therapeutics, Inc. - SPRO CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Biaya inap posisi Long

Long position overnight fee

Margin. Your investment $1,000.00
Biaya Overnight -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Kunjungi platform
-0.024068%
Biaya inap posisi short

Short position overnight fee

Margin. Your investment $1,000.00
Biaya Overnight 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Kunjungi platform
0.001846%
Waktu biaya inap 21:00 (UTC)
Kuantitas min. yang diperdagangkan 1
Mata uang USD
Margin 20%
Bursa efek United States of America
Komisi perdagangan 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 0.68-9.00
Average Volume (10 days) 646.65K
Average Volume (3 months) 9.28M
Market Cap 72.49M
P/E Ratio -100.00K
Shares Outstanding 51.78M
Revenue 8.81M
EPS -3.11
Dividend (Yield %) N/A
Beta 0.88
Next Earnings Date Mar 30, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Spero Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 18.256 9.33 18.147 3.966 1.979
Revenue 18.256 9.33 18.147 3.966 1.979
Total Operating Expense 106.227 88.443 81.363 46.772 43.709
Selling/General/Admin. Expenses, Total 41.701 21.44 15.588 12.887 10.84
Research & Development 64.526 67.003 65.775 33.885 32.869
Operating Income -87.971 -79.113 -63.216 -42.806 -41.73
Interest Income (Expense), Net Non-Operating -1.39 0.401 1.551 0 1.541
Other, Net -0.395 0.432 0.74 1.144 0.303
Net Income Before Taxes -89.756 -78.28 -60.925 -41.662 -39.886
Net Income After Taxes -89.756 -78.28 -60.925 -41.662 -39.886
Minority Interest 0 1.143
Net Income Before Extra. Items -89.756 -78.28 -60.925 -41.662 -38.743
Net Income -89.756 -78.28 -60.925 -41.662 -38.743
Total Adjustments to Net Income 0 -0.549 0 -7.354
Income Available to Common Excl. Extra. Items -89.756 -78.829 -60.925 -41.662 -46.097
Income Available to Common Incl. Extra. Items -89.756 -78.829 -60.925 -41.662 -46.097
Dilution Adjustment
Diluted Net Income -89.756 -78.829 -60.925 -41.662 -46.097
Diluted Weighted Average Shares 30.8958 22.3861 18.1605 16.0018 14.3692
Diluted EPS Excluding Extraordinary Items -2.90512 -3.52133 -3.3548 -2.60358 -3.20805
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -2.90512 -3.52133 -3.3548 -2.60358 -3.20805
Total Extraordinary Items 0 0
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 2.069 2.744 3.064 5.148 7.3
Revenue 2.069 2.744 3.064 5.148 7.3
Total Operating Expense 32.276 30.246 25.588 23.69 26.703
Selling/General/Admin. Expenses, Total 15.305 13.021 11.152 9.229 8.299
Research & Development 16.971 17.225 14.436 14.461 18.404
Operating Income -30.207 -27.502 -22.524 -18.542 -19.403
Interest Income (Expense), Net Non-Operating -2.609 -1.66 0.09 0.082 0.098
Other, Net -0.013 -0.078 -0.087 -0.112 -0.118
Net Income Before Taxes -32.829 -29.24 -22.521 -18.572 -19.423
Net Income After Taxes -32.829 -29.24 -22.521 -18.572 -19.423
Net Income Before Extra. Items -32.829 -29.24 -22.521 -18.572 -19.423
Net Income -32.829 -29.24 -22.521 -18.572 -19.423
Income Available to Common Excl. Extra. Items -32.829 -29.24 -22.521 -18.572 -19.423
Income Available to Common Incl. Extra. Items -32.829 -29.24 -22.521 -18.572 -19.423
Diluted Net Income -32.829 -29.24 -22.521 -18.572 -19.423
Diluted Weighted Average Shares 32.6067 32.3311 32.1325 29.6754 29.4142
Diluted EPS Excluding Extraordinary Items -1.00682 -0.90439 -0.70088 -0.62584 -0.66033
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.00682 -0.90439 -0.70088 -0.62584 -0.66033
Total Adjustments to Net Income 0 0
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 157.872 139.145 95.414 124.219 92.059
Cash and Short Term Investments 146.402 126.906 82.045 115.443 87.288
Cash & Equivalents 112.584 85.209 29.73 34.08 87.288
Total Receivables, Net 2.641 6.176 8.546 1.298 2.943
Prepaid Expenses 8.829 6.063 4.823 7.478 1.828
Total Assets 171.072 153.451 106.103 129.006 93.479
Property/Plant/Equipment, Total - Net 7.556 8.783 7.148 2.893 1.164
Property/Plant/Equipment, Total - Gross 10.436 11.059 8.663 3.72 1.807
Accumulated Depreciation, Total -2.88 -2.276 -1.515 -0.827 -0.643
Note Receivable - Long Term 0 0.311 0.021 0.233 0
Other Long Term Assets, Total 5.644 5.212 3.52 1.661 0.256
Total Current Liabilities 18.67 14.343 26.663 12.318 8.157
Accounts Payable 1.101 1.155 4.147 3.603 3.47
Accrued Expenses 15.712 13.188 22.516 8.263 4.321
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.857 0 0.452 0.366
Total Liabilities 82.783 21.411 31.529 13.506 8.877
Total Long Term Debt 48.414 0 0 0 0
Minority Interest 0.355 0.355
Other Liabilities, Total 15.699 7.068 4.866 0.833 0.365
Total Equity 88.289 132.04 74.574 115.5 84.602
Redeemable Preferred Stock 0 0
Common Stock 0.032 0.029 0.019 0.017 0.014
Additional Paid-In Capital 455.719 409.722 273.966 254.013 181.428
Retained Earnings (Accumulated Deficit) -367.463 -277.707 -199.427 -138.502 -96.84
Total Liabilities & Shareholders’ Equity 171.072 153.451 106.103 129.006 93.479
Total Common Shares Outstanding 32.3937 29.2603 19.1907 17.206 14.3692
Short Term Investments 33.818 41.697 52.315 81.363
Other Equity, Total -0.002 -0.007 0.016 -0.028
Preferred Stock - Non Redeemable, Net 0.003 0.003
Total Preferred Shares Outstanding 3.21815 3.21829
Long Term Debt 48.414
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 132.704 157.872 131.769 106.316 129.492
Cash and Short Term Investments 121.966 146.402 123.417 99.218 115.676
Cash & Equivalents 72.111 112.584 112.859 71.562 77.042
Short Term Investments 49.855 33.818 10.558 27.656 38.634
Total Receivables, Net 1.991 2.641 2.584 2.197 8.622
Prepaid Expenses 8.747 8.829 5.768 4.901 5.194
Total Assets 145.83 171.072 144.691 119.594 143.44
Property/Plant/Equipment, Total - Net 7.197 7.556 7.71 8.067 8.425
Note Receivable - Long Term 0 0 0 0.311
Other Long Term Assets, Total 5.929 5.644 5.212 5.211 5.212
Total Current Liabilities 69.199 18.67 17.258 12.826 17.763
Accounts Payable 4.78 1.101 3.161 1.632 3.825
Accrued Expenses 10.429 15.712 12.398 10.015 13.938
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 83.357 82.783 32.796 29.342 24.594
Total Long Term Debt 0 48.414 0 0 0
Other Liabilities, Total 14.158 15.699 15.538 16.516 6.831
Total Equity 62.473 88.289 111.895 90.252 118.846
Preferred Stock - Non Redeemable, Net 0.003 0.003 0.003 0.003 0.003
Common Stock 0.033 0.032 0.032 0.03 0.03
Additional Paid-In Capital 462.735 455.719 450.085 405.923 415.946
Retained Earnings (Accumulated Deficit) -400.292 -367.463 -338.223 -315.702 -297.13
Other Equity, Total -0.006 -0.002 -0.002 -0.002 -0.003
Total Liabilities & Shareholders’ Equity 145.83 171.072 144.691 119.594 143.44
Total Common Shares Outstanding 32.7556 32.3937 32.2203 29.6992 29.6639
Total Preferred Shares Outstanding 3.21815 3.21815 3.21815 3.21815 3.21815
Other Current Liabilities, Total 53.99 1.857 1.699 1.179
Long Term Debt 0 48.414
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -89.756 -78.28 -60.925 -41.662 -39.886
Cash From Operating Activities -64.347 -85.872 -50.02 -39.625 -39.111
Cash From Operating Activities 0.646 0.761 0.75 0.409 0.363
Non-Cash Items 11.901 5.111 3.376 2.699 -0.031
Changes in Working Capital 12.862 -13.464 6.779 -1.071 0.443
Cash From Investing Activities 7.672 10.47 29.53 -83.156 -0.027
Capital Expenditures -0.157 -0.314 -2.436 -0.027
Cash From Financing Activities 84.05 130.881 16.14 69.523 116.111
Financing Cash Flow Items 47.232 -0.953 -0.158 -1.312 -4.749
Issuance (Retirement) of Stock, Net 36.818 131.834 16.298 70.835 120.86
Net Change in Cash 27.375 55.479 -4.35 -53.258 76.973
Other Investing Cash Flow Items, Total 7.672 10.627 29.844 -80.72
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -32.829 -89.756 -60.516 -37.995 -19.423
Cash From Operating Activities -28.223 -64.347 -36.998 -32.046 -15.479
Cash From Operating Activities 0.189 0.646 0.455 0.307 0.159
Non-Cash Items 6.117 11.901 7.327 4.708 2.253
Changes in Working Capital -1.7 12.862 15.736 0.934 1.532
Cash From Investing Activities -16.064 7.672 30.947 13.922 3.003
Other Investing Cash Flow Items, Total -16.064 7.672 30.947 13.922 3.003
Cash From Financing Activities 3.814 84.05 33.701 4.477 4.309
Financing Cash Flow Items 0 47.232 -0.411 -0.146 -0.037
Issuance (Retirement) of Stock, Net 3.814 36.818 34.112 4.623 4.346
Net Change in Cash -40.473 27.375 27.65 -13.647 -8.167
Capital Expenditures 0 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
GSK plc Corporation 17.7507 9190606 7450000 2022-11-14 MED
Anson Funds Management LP. Hedge Fund 5.8321 3019608 1545736 2022-12-31 HIGH
Atlas Venture Venture Capital 4.651 2408128 0 2022-12-31 LOW
Pfizer Inc Corporation 4.5626 2362348 0 2022-07-20 MED
AWM Investment Company, Inc. Investment Advisor/Hedge Fund 2.5116 1300400 -1000000 2022-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0364 1054388 665 2022-12-31 LOW
Alphabet, Inc. Venture Capital 1.7189 889979 0 2022-12-31 LOW
Millennium Management LLC Hedge Fund 1.6927 876398 188002 2022-12-31 HIGH
Murchinson Ltd. Investment Advisor/Hedge Fund 1.4731 762700 0 2022-12-31 HIGH
Rock Springs Capital Management LP Hedge Fund 1.2931 669533 -101177 2022-12-31 LOW
Mahadevia (Ankit) Individual Investor 1.1307 585445 519628 2023-02-03 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.9252 479031 -187473 2022-12-31 LOW
Hamed (Kamal) Individual Investor 0.9193 475957 265957 2023-02-01 MED
Novo Holdings A/S Venture Capital 0.9056 468902 0 2022-12-31 LOW
XTX Markets LLC Investment Advisor 0.6697 346734 346734 2022-12-31 HIGH
Renaissance Technologies LLC Hedge Fund 0.6623 342900 128200 2022-12-31 HIGH
Keutzer (Timothy) Individual Investor 0.6318 327144 262563 2023-02-02 LOW
Joseph (Tamara) Individual Investor 0.627 324644 262563 2023-02-02 LOW
Oasis Management Company Ltd. Investment Advisor/Hedge Fund 0.5562 288000 0 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4969 257284 -32974 2022-12-31 LOW

Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

Capital.com Group

500K+

Trader

92K+

Klien aktif per bulan

$53M+

Volume investasi per bulan

$30M+

Penarikan tiap bulan

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Laba/Loss
Industry: Bio Therapeutic Drugs

675 Massachusetts Ave Ste 14
CAMBRIDGE
MASSACHUSETTS 02139-3309
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

70.22 Price
+0.390% 1D Chg, %
Biaya inap posisi Long -0.0170%
Biaya inap posisi short -0.0050%
Waktu biaya inap 21:00 (UTC)
Spread 0.03

BTC/USD

27,371.35 Price
+0.090% 1D Chg, %
Biaya inap posisi Long -0.0616%
Biaya inap posisi short 0.0137%
Waktu biaya inap 21:00 (UTC)
Spread 60.00

XRP/USD

0.42 Price
-0.920% 1D Chg, %
Biaya inap posisi Long -0.0753%
Biaya inap posisi short 0.0069%
Waktu biaya inap 21:00 (UTC)
Spread 0.00381

US100

12,638.60 Price
+0.540% 1D Chg, %
Biaya inap posisi Long -0.0241%
Biaya inap posisi short 0.0018%
Waktu biaya inap 21:00 (UTC)
Spread 1.8

Masih mencari broker yang bisa Anda percayai?

Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda